Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-31
2005-05-31
Desai, Rita (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S144000
Reexamination Certificate
active
06900233
ABSTRACT:
A substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-one, compound of formula 1,wherein R1, R2, R3, R4and R5are as defined herein, pharmaceutical composition comprising the compound and use of the compound for inhibiting pancreatic lipase, or the prophylaxis or treatment of obesity are described.
REFERENCES:
patent: 4150142 (1979-04-01), Boesch
patent: 5093343 (1992-03-01), Bonse et al.
patent: 5236939 (1993-08-01), Bonse
patent: 6369088 (2002-04-01), Schoenafinger et al.
patent: 6596742 (2003-07-01), Petry et al.
patent: 2603877 (1976-08-01), None
patent: 2604110 (1976-08-01), None
patent: 0048040 (1984-08-01), None
patent: 0067471 (1985-11-01), None
patent: 0419918 (1991-04-01), None
patent: WO 01/17981 (2001-03-01), None
patent: WO 01/66531 (2001-09-01), None
1985, CAS:103:178266.
Bauer Armin
Heuer Hubert Otto
Möller Günter
Petry Stefan
Schoenafinger Karl
Aventis Pharma Deutschland GmbH
Desai Rita
Rossi Joseph D.
Shiao Robert
LandOfFree
Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3410174